nPacific Edge Limited announced it is advancing its clinical evidence generation program with LOBSTER - a clinical study focused on demonstrating the clinical utility of Cxbladder Monitor for surveillance of recurrent urothelial cancer against the current American Urological Association (AUA) standard of care targeting existing guidelines language for greater inclusion of Cxbladder.
Pacific Edge has contracted two sites, has initiated one site to date, and expects to enrol the first patient in LOBSTER this quarter. Cxbladder Monitor is a urine-based gene expression biomarker test for the surveillance of recurrent disease in bladder cancer patients. International peer reviewed publications1,2,3 have already shown the test's success in identifying those patients with a prior history of urothelial cancer that have a low probability of disease recurrence. By identifying these patients, healthcare providers are able to introduce a significant change in clinical practice, enabling all patients who test negative, to safely undergo cystoscopies at longer intervals than submitting to a cystoscopy at every visit, the AUA's current standard of care.
This outcome significantly reduces the burden of invasive and expensive cystoscopic evaluations; spares patients the potential risks, discomfort and anxiety from cystoscopy, without compromising detection rates. It can also free up resources to be focused on patients most in need and facilitate compliance with cancer surveillance and management regimes.